Beam Therapeutics shares fall 1.59% intraday after Q2 net loss widens more than expected.

Tuesday, Aug 5, 2025 2:28 pm ET1min read
Beam Therapeutics Inc. declined 1.59% in intraday trading, with the company reporting a wider-than-expected net loss for Q2. The company's revenue also fell, contributing to the negative sentiment surrounding the stock.

Beam Therapeutics shares fall 1.59% intraday after Q2 net loss widens more than expected.

Comments



Add a public comment...
No comments

No comments yet